Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase III AIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) met its primary efficacy endpoint of change at Day 28 from baseline in respiratory symptoms, as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a patient-reported outcome (PRO) tool used to measure health-related quality of life for people with CF. Data from the 164-patient, double-blinded, randomized study demonstrated a significant improvement in the CFQ-R, with a treatment difference in mean change from baseline of 9.7 points in the respiratory domain (on a scale of 100) compared to placebo (p less than 0.001) following a 28-day treatment course with 75 mg aztreonam lysine for inhalation or volume-matched placebo administered three times daily by the PARI eFlow(R) Electronic Nebulizer. Aztreonam lysine-treated patients also experienced significant improvements at Day 28 in respiratory function, as measured by relative improvement of FEV1, with a treatment difference in mean change from baseline of 10.3 percent versus placebo (p less than 0.001). Full study results will be submitted for presentation at an upcoming scientific meeting.

The most common treatment-emergent adverse events in this study were cough, productive cough, nasal congestion, sore throat and dyspnea (shortness of breath). The incidences of these events were not significantly different between the placebo and the aztreonam lysine groups.

"The FDA, Cystic Fibrosis Foundation and medical community have identified PROs as important endpoints in clinical trials for CF and a variety of other diseases," said A. Bruce Montgomery, MD, Senior Vice President, Head of Respiratory Therapeutics, Gilead Sciences. "AIR-CF1 is the first Phase II
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... 26, 2015  Mobility Ventures LLC, an AM General ... of America (NYSE: BAC ) that will ... of the revolutionary MV-1 - - the world,s first ... up to provide safe and comfortable transportation for all ... loan to purchase a new MV-1 vehicle at the ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... The National Association of Boards of Pharmacy® (NABP®) ... endanger the lives of unsuspecting American consumers by ... without requiring a valid prescription. By implementing safeguards, ... consumers in identifying safe Internet pharmacies, The Online ...
... Inc., a global leader in engineering services, is ... a U.S. General Services Administration (GSA) Schedule 871 ... "Waltonen currently provides engineering services to numerous government ... (TARDEC), Tank Automotive Command (TACOM), the U.S. Air ...
Cached Medicine Technology:NABP Supports Legislation Aimed to Protect Patients from Counterfeit Drugs and Fake Online Pharmacies 2NABP Supports Legislation Aimed to Protect Patients from Counterfeit Drugs and Fake Online Pharmacies 3
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
(Date:2/28/2015)... In a recent episode of SCI TV ... Athlete Development Services and Consultancy talks with Joshua ... development and player engagement during and after their careers. ... face and how off-field activities are a critical component ... in athlete development issues while in graduate school coaching ...
(Date:2/28/2015)... Morristown, NJ (PRWEB) February 28, 2015 ... Month—is a good time to remind ourselves and ... be ignored, say Atlantic NeuroSurgical Specialists (ANS). , ... (TBI), which account for 75% of TBIs. There ... word concussion may sound benign, but it is ...
(Date:2/28/2015)... For those people who are unable to attend ... Research Foundation (Meso Foundation) will broadcast its Symposium ... 9:30 AM. , The live broadcast is free of ... accessed through any browser on a computer or smartphone/device ... a unique event that covers important treatment information and ...
(Date:2/28/2015)... February 28, 2015 India Network ... sponsored visitor health insurance programs for visitors coming to ... Indian elderly parents traveling to the United States are ... diabetes and blood pressure. These diseases are so common ... list them as medical conditions. There were 66.8 million ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... future physicians are to best serve the changing health ... put greater emphasis on public health and prevention, experts ... of Preventive Medicine (AJPM). The supplement, including ... top medical educators and public health professionals, is sponsored ...
... Tropical Diseases will publish an article emphasizing the ... Asia on Tuesday, Sept. 27th. According to the article,s ... Institute, and Dr. Ken Alibek of Nazarbayev University in ... post-Soviet economic breakdown that may have contributed to a ...
... been honored with the Presidential Early Career Award ... and scientific leadership. It is the highest honor ... engineering professionals in the early stages of their ... Sept. 26. Justin Kasper, an astrophysicist at ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, Sept. ... who undergo surgery to open up clogged arteries in the ... their surgeon is inexperienced, although the risk is still small. ... of these patients, said study author Dr. Brahmajee K. Nallamothu, ...
... window of opportunity to receive treatment to save their brain ... medical researchers in Lancet Neurology. The review, ... Shuaib and his colleagues. Shuaib, the senior author, is a ... Medicine & Dentistry at the University of Alberta. He is ...
... by scientists at the University of California, San Diego ... proteasome phosphatase that appears to regulate removal of damaged ... this process works could have important implications for numerous ... led by Jack E. Dixon, PhD, professor of ...
Cached Medicine News:Health News:Medical education needs more of a public health and prevention focus 2Health News:Central Asia's hidden burden of neglected tropical diseases 2Health News:President Barack Obama recognizes outstanding scientists at the Smithsonian 2Health News:Surgeon Experience Matters in Neck Artery Procedure: Study 2Health News:Window of opportunity to treat some stroke patients may be longer than originally suspected 2Health News:Researchers identify enzyme that regulates degradation of damaged proteins 2
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Medicine Products: